Skip to Content

Join the 'Netspot' group to help and get support from people like you.

Netspot News

FDA Approves Netspot (gallium Ga 68 dotatate) Imaging Agent to Detect Rare Neuroendocrine Tumors

Posted 16 Jun 2016 by Drugs.com

June 1, 2016 – The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs). NETs are rare noncancerous (benign) or cancerous (malignant) tumors that develop in the hormone-producing cells of the body’s neuroendocrine system. These cells are found throughout the body in organs, such as the stomach, intestines, pancreas, lungs and other locations. NETs have receptors for somatostatin, a hormone that regulates the endocrine system. Ga 68 dotatate, a positron emitting analogue of somatostatin, works by binding to such receptors. "Use of advanced imaging techniques to detect rare ... Read more

Related support groups: Diagnosis and Investigation, Neuroendocrine Carcinoma, Positron Emission Tomography Imaging, Netspot

Ask a Question

Further Information

Related Condition Support Groups

Positron Emission Tomography Imaging

Netspot Patient Information at Drugs.com